Company
United StatesPublic company, NASDAQ: NBIXNeurocrine Biosciences Inc (NASDAQ: NBIX), San Diego, CA – FDA Inspections
Inspection records and compliance data for Neurocrine Biosciences Inc in San Diego, California. 2 FDA inspections on record, last inspected July 18, 2024. Publicly traded as NASDAQ: NBIX.
Company Profile
This profile covers Neurocrine Biosciences Inc based in San Diego, California, United States.
FDA Inspection History
- FDA inspections
- 2
- OAI
- 0
- VAI
- 1
- NAI
- 1
- Form 483s
- 0
- Warning letters
- 0
First inspected December 2, 2016. Last inspected July 18, 2024.
Most cited issue areas
- Failure to develop written procedures1 inspection
FDA inspections (2)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| July 18, 2024 | VAI | Human Drugs · Postmarket Surv. and Epidemiology | 1244087 |
| December 2, 2016 | NAI | Human Drugs · Bioresearch Monitoring | 998843 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Neurocrine Biosciences Inc
Stock ticker
NBIX
Exchange
NASDAQ
Share price
$160.29
Market cap
$16.2B
Price as of
November 6, 2026
FEI Number
1000202524
Address
12790 El Camino Real, San Diego, California 92130, United States
Country
United States
ID: 6c40dcc4-1aa2-43ea-ac52-032e79ec83c0